NEWS
Print Your Certificate
The 2025 AD Scientific Index is here—explore updated university and researcher rankings!
New! Young University / Institution Rankings 2025
New! The 2025 Edition of the AD Scientific Index is now live!
New! Art & Humanities Rankings 2025
New! Social Sciences and Humanities Rankings 2025
"Exciting Update! The 2025 Edition of the AD Scientific Index is now live!
AD
Scientific Index 2025
Scientist Rankings
University Rankings
Subject Rankings
Country Rankings
login
Login
person_add
Register
insights
H-Index Rankings
insights
i10 Productivity Rankings
format_list_numbered
Citation Rankings
subject
University Subject Rankings
school
Young Universities
format_list_numbered
Top 100 Scientists
format_quote
Top 100 Institutions
format_quote
Compare & Choose
local_fire_department
Country Reports
person
Find a Professional
Moises A Huaman
University of Cincinnati - Cincinnati / United States
Others
AD Scientific Index ID: 1773478
Registration, Add Profile,
Premium Membership
Print Your Certificate
Ranking &
Analysis
Job
Experiences (0)
Education
Information (0)
Published Books (0)
Book Chapters (0)
Articles (0)
Presentations (0)
Lessons (0)
Projects (0)
Congresses (0)
Editorship, Referee &
Scientific Board (0 )
Patents /
Designs (0)
Academic Grants
& Awards (0)
Artistic
Activities (0)
Certificate / Course
/ Trainings (0)
Association &
Society Memberships (0)
Contact, Office
& Social Media
person_outline
Moises A Huaman's MOST POPULAR ARTICLES
1-)
Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trialPB Gilbert, DC Montefiori, AB McDermott, Y Fong, D Benkeser, W Deng, ...Science 375 (6576), 43-50, 20224872022
2-)
Early outpatient treatment for Covid-19 with convalescent plasmaDJ Sullivan, KA Gebo, S Shoham, EM Bloch, B Lau, AG Shenoy, ...New England Journal of Medicine 386 (18), 1700-1711, 20221062022
3-)
Tuberculosis and cardiovascular disease: linking the epidemicsMA Huaman, D Henson, E Ticona, TR Sterling, BA GarvyTropical diseases, travel medicine and vaccines 1, 1-7, 2015952015
4-)
Effect of subcutaneous casirivimab and imdevimab antibody combination vs placebo on development of symptomatic COVID-19 in early asymptomatic SARS-CoV-2 infection: a randomized …MP O’Brien, E Forleo-Neto, N Sarkar, F Isa, P Hou, KC Chan, BJ Musser, ...Jama 327 (5), 432-441, 20221092022
5-)
Prevalence, risk factors, and treatment outcomes of isoniazid-and rifampicin-mono-resistant pulmonary tuberculosis in Lima, PeruL Villegas, L Otero, TR Sterling, MA Huaman, P Van der Stuyft, E Gotuzzo, ...PloS one 11 (4), e0152933, 20161002016
ARTICLES
Add your articles
We use cookies to personalize our website and offer you a better experience. If you accept cookies, we can offer you special services.
Cookie Policy
Accept